- Home
- LGVN vs EQ Comparison
LGVN vs EQ Comparison
Compare LGVN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- EQ
- Stock Information
- Founded
- LGVN 2014
- EQ 2017
- Country
- LGVN United States
- EQ United States
- Employees
- LGVN 25
- EQ N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- EQ Health Care
- Exchange
- LGVN Nasdaq
- EQ Nasdaq
- Market Cap
- LGVN 11.5M
- EQ 13.1M
- IPO Year
- LGVN 2021
- EQ 2018
- Fundamental
- Price
- LGVN $0.81
- EQ $1.35
- Analyst Decision
- LGVN Strong Buy
- EQ Buy
- Analyst Count
- LGVN 3
- EQ 3
- Target Price
- LGVN $6.33
- EQ $3.00
- AVG Volume (30 Days)
- LGVN 1.9M
- EQ 21.8M
- Earning Date
- LGVN 08-13-2025
- EQ 08-14-2025
- Dividend Yield
- LGVN N/A
- EQ N/A
- EPS Growth
- LGVN N/A
- EQ N/A
- EPS
- LGVN N/A
- EQ N/A
- Revenue
- LGVN $2,073,000.00
- EQ $16,553,000.00
- Revenue This Year
- LGVN N/A
- EQ N/A
- Revenue Next Year
- LGVN $51.48
- EQ N/A
- P/E Ratio
- LGVN N/A
- EQ N/A
- Revenue Growth
- LGVN 68.67
- EQ N/A
- 52 Week Low
- LGVN $0.63
- EQ $0.27
- 52 Week High
- LGVN $2.86
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- LGVN 30.47
- EQ 77.37
- Support Level
- LGVN $0.63
- EQ $0.78
- Resistance Level
- LGVN $0.94
- EQ $1.25
- Average True Range (ATR)
- LGVN 0.16
- EQ 0.23
- MACD
- LGVN -0.09
- EQ 0.06
- Stochastic Oscillator
- LGVN 11.37
- EQ 77.78
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.